Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.
Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.
The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.
Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.
Price (AUD): $12.99, Change: $+0.29, Percent Change: +2.28%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.